General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade -a single-center retrospective study

详细信息    查看全文

• 作者：Juan Li ; Guowei Dai ; Zhuoli Zhang
• 关键词：Adverse drug reaction ; Autoimmune diseases ; Cyclophosphamide
• 刊名：Clinical Rheumatology
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：34
• 期：2
• 页码：273-278
• 全文大小：130 KB
• 参考文献：1. Brummaier T, Pohanka E, Studnicka-Benke A et al (2013) Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med 24:590-96 CrossRef
  2. Sladek NE (1973) Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res 33:1150-158
  3. Struck RF, Kirk MC, Witt MH et al (1975) Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom 2:46-2 CrossRef
  4. Alarcon RA (1976) Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation. Cancer Treat Rep 60:327-35
  5. Gurtoo HL, Marinello AJ, Struck RF et al (1981) Studies on the mechanism of denaturation of cytochrome P-450 by cyclophosphamide and its metabolites. J Biol Chem 256:11691-1701
  6. Koss LG (1967) A light and electron microscopic study of the effects of a single dose of cyclophosphamide on various organs in the rat: I. The urinary bladder. Lab Investig 16:44-5
  7. Brock N, Stekar J, Pohl J et al (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 29:659-61
  8. Xie H, Griskevicius L, Stahle L et al (2006) Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 27:54-1 CrossRef
  9. Lawrence HJ, Simone J, Aur RJ (1975) Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. Cancer 36:1572-576 CrossRef
  10. Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG et al (2002) Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 41:780-86 CrossRef
  11. Bennett AH (1974) Cyclophosphamide and hemorrhagic cystitis. J Urol 111:603-06
  12. Youssef M, Mokni S, Belhadjali H et al (2013) Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation. Int J Clin Pharm 35:309-12 CrossRef
  13. Shah PC, Rao KR, Patel AR (1978) Cyclophosphamide induced nail pigmentation. Br J Dermatol 98:675-80 CrossRef
  14. Vulsteke C, Lambrechts D, Dieudonne A et al (2013) Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24:1513-525 CrossRef
  15. Zhong S, Huang M, Yang X et al (2006) Relationship of glutathione / S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 62:457-72 CrossRef
  16. Beard ME, Conder JL, Clark VA (1984) Ovarian failure following cytotoxic therapy. N Z Med J 97:759-62
  17. Somers EC, Marder W, Christman GM et al (2005) Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52:2761-767 CrossRef
  18. Pasoto SG, Mendonca BB, Bonfa E (2002) Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 11:175-80 CrossRef
  19. Shabanova SS, Ananieva LP, Alekberova ZS et al (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26:436-41
  20. Manger K, Wildt L, Kalden J
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  
• 出版者：Springer London
• ISSN：1434-9949

文摘

This study was conducted to investigate the adverse reaction to cyclophosphamide (CYC) in Chinese patients with systemic autoimmune diseases. Patients with systemic autoimmune diseases who were exposed to CYC and followed up regularly for at least 2?years in Rheumatology Department during June 2003 to June 2013 were enrolled into this study. Participants were divided into per oral (PO) group and intravenous (IV) group. The adverse effects to CYC were recorded and analyzed. A total of 419 patients were enrolled in this study. The occurrence rates of gastrointestinal discomfort, alopecia, myelosuppression, secondary infection, abnormal liver function, dizziness/headache, menstrual disturbance and reversal to normal menstruation after discontinuation of CYC were 21.5?%, 12.4?%, 7.4?%, 3.6?%, 3.1?%, 3.1?%, 30.3?% and 31.0?%, respectively. None of the patients had hemorrhagic cystitis. The significant risk factors for gastrointestinal discomfort were female, exposure to CYC for a long time and intravenous route. Risk factors for mylosuppression were female and combination with other immunosuppressants. Risk factors were female gender for alopecia and older age for menstrual disturbance. Female patients were much more likely to have gastrointestinal discomfort, mylosuppression and alopecia when CYC was administrated intravenously. Risk factors were older age for menstrual disturbance and the combination with other immunosuppressants for myelosuppression. Hemorrhagic cystitis did not appear in our series for the possible reason of prophylactic hydration before intravenous injection and maybe racial difference.